A drug that targets the GLP-1 pathway is being considered for treating plaque psoriasis. Research suggests it may be effective as an adjunct therapy for select patients, potentially improving quality of life when used in combination with biologics. The treatment landscape for psoriasis is evolving, with various therapies and medications being explored or expanded, including some that may be subject to Medicare price negotiations.